Figure 3.

Anti-neoplastic effects of MF-15 in prostate cancer spheroids. (A) 22Rv1, DuCaP, and DuCaP EnzaR (8000 cells per well) or (C,E) DuCaP and DuCaP Enza R with GFP-labeled CAFs at a ratio of 1:1 (4000 + 4000 cells per well) were seeded into ULC 96-well plates (Corning) and allowed to form spheroids over 4 days. MF-15 (10 µM), indomethacin (indo, 20 µM), AKRi (50 µM), enzalutamide (5 µM) and a combination of enzalutamide (5 µM) with MF-15 (10 µM) were added at days 4 and 8 in RPMI + 10% CS-FCS. (B,D,F) Spheroid size was determined at day 10, and (A,C,E) representative images were taken with IncuCyte S3 software. Data represent the mean ±SEM from three independent experiments. Statistical comparisons to the mock control were expressed with an asterisk (* p < 0.05, ** p < 0.01, *** p < 0.001) and comparisons to enzalutamide with a hash key (#).